Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy

Journal of Immunotherapy

Volumn 19, Issue 1, 1996, Pages 69-80

  Olencki, T ^a,b   Finke, J ^a,b   Tubbs, R ^b   Tuason, L ^b   Greene, T ^b   McLain, D ^b   Swanson, S J ^c   Herzog, P ^a   Stanley, J ^b   Edinger, M ^b   Budd, G T ^b   Bukowski, R M ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Immunomodulatory; Interleukin 2; Interleukin 4; Phase I

Indexed keywords

CD16 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; DIPHENHYDRAMINE; HLA DR ANTIGEN; INDOMETACIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; PARACETAMOL; PETHIDINE; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL STRAIN K 562; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MELANOMA; MYOCARDITIS; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0042071830     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199601000-00008     Document Type: Article

References (39)

1. Smith KA. Interleukin-2: inception, impact and implications. Science 1988;240:1169-76.
2. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135: 2865-75.
3. Talmadge JE, Chirigos MA. Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers. Springer Semin Immunopathol 1985;8: 429-43.
4. Yang JC, Perry-Lalley D, Rosenberg SA. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod 1990; 9:149-59.
5. Rosenberg SA, Mule JJ, Speiss PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-88.
6. Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (rlL-2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 1985; 135:4273-80.
7. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
8. Rosenberg SA. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10: 180-99.
9. Yokota T, Arai N, de Vries J, et al. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells. Immunol Rev 1988;102:137-87.
10. Zlotnik A, Ransom J. Frank G, et al. Interleukin-4 is a growth factor for activated thymocytes: possible role in T-cell ontogeny. Proc Natl Acad Sci USA 1987;84:3856-60.
11. Spits H, Yssel H, Takebe Y. et al. Recombinant interleukin 4 promotes the growth of human T cells. J Immunol 1987; 139:1142-7.
12. Romani N, Gruner S. Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
13. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
14. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
15. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-16,
16. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988;168: 2183-91.
17. Spits H, Yssel H, Paliard X, et al. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 1988; 141:29-36.
18. Budd GT, Murthy S, Finke J, et al. Phase I trial of high-dose bolus interleukin-2 and interferon alpha-2a in patients with metastatic malignancy. J Clin Oncol 1992;10:804-9.
19. Tubbs RR, Sheibani K. Immunohistology of lymphoproliferative disorders. Semin Diagn Pathol 1984;1:272-84.
20. Caulfield MJ, Barna B, Murthy S, et al. Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-α in patients with malignant melanoma. J Biol Response Mod 1990;9:319-28.
21. + tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 1990;50:2363-70.
22. Bukowski RM, Budd GT, Gibbons JA, et al. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 1994;12:97-106.
23. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945;1:80-3.
24. Mack G, Skillings J. A Friedman-type rank test for main effects in a two-factor ANOVA. J Am Stat Assoc 1980;75: 947-51.
25. Lotze M. Role of IL-4 in the antitumor response. In: Spitz H, ed. IL-4: structure and function. Boca Raton, FL: CRC Press, 1992:237.
26. Lotze MT. The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes. Hum Gene Ther 1992;3:167-77.
27. Sosman J, Fisher SG, Kefer C, et al. A phase I trial of continuous infusion interleukin-4 alone and following interleukin-2 in cancer patients. Ann Oncol 1994;5:447-552.
28. Whitehead R, Friedman K, Clark D. A phase I trial of subcutaneous interleukin-2 and interleukin-4 [Abstract]. Proc Am Assoc Cancer Res 1992;33:1381.
29. Rubin JT, Lotze MT. Acute gastric mucosal injury associated with the systemic administration of interleukin-4. Surgery 1992;111:274-280.
30. Markowitz A, Kleinerman E, Hudson M, et al. Phase I study of recombinant human interleukin-4 (rHuIL-4) in patients with advanced cancer [Abstract]. Blood 1989;74(suppl): 146a.
31. Gilleece MH, Scarffee JH, Ghosh A, et al. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections - a phase I dose toxicity trial. Br J Cancer 1992;66: 204-10.
32. Trehu EG, Isner JM, Mier JW, et al. Possible myocardial toxicity associated with interleukin-4 therapy. J Immunother 1993;14:348-51.
33. Ghosh AK, Smith NK, Prendiville J, et al. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. Eur Cytokine Netw 1993;4: 205-11.
34. Thompson JA, Lee DJ, Lindgren CG, et al. Infuence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988;6:669-78.
35. Sosman J, Kohler P, Hank J, et al. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988;80:1451-61.
36. Kawakami Y, Custer MC, Rosenberg SA, et al. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J Immunol 1989;142:3452-61.
37. Higuchi CM, Thompson JA, Lindgren CG, et al. Induction of lymphokine-activated killer activity by interleukin-4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res 1989;49:6487-92.
38. Puri RK, Siegel JP. Interleukin-4 and cancer therapy. Cancer Invest 1993;11:473-86.
39. Rubin JT, Elwood LJ, Rosenberg SA, et al. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 1989;49:7086-92.